PROPHASE LABS, INC. (NASDAQ:PRPH) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 18, 2017, ProPhase Labs, Inc. (the Company) held its
Annual Meeting of Stockholders (the Annual Meeting). As at
the record date of April 18, 2017, the Company had 17,080,776
shares of common stock, par value $0.0005 per share (the Common
Stock), outstanding and entitled to vote at the Annual Meeting.
The following is a listing of the votes cast for or withheld, and
the number of broker non-votes, with respect to each nominee for
director and a listing of the votes cast for and against, as well
as abstentions and broker-non votes, with respect to the vote to
ratify the appointment of EisnerAmper LLP as the Companys
independent registered public accounting firm for the fiscal year
ending December 31, 2017. At the Annual Meeting, the Companys
stockholders (i) elected each nominee as a director to serve as a
director until the next annual meeting of stockholders and until
his successor is duly elected and qualified and (ii) ratified the
appointment of EisnerAmper LLP as the Companys independent
registered public accounting firm for the fiscal year ending
December 31, 2017.
| 1. | Directors Information: |
| Number of Shares | ||||||||||||
| Director | For | Withheld | Broker Non-Votes | |||||||||
| 1. Ted Karkus | 9,325,971 | 2,626,779 | 3,673,436 | |||||||||
| 2. Jason Barr | 9,484,064 | 2,468,686 | 3,673,436 | |||||||||
| 3. Mark Burnett | 9,326,011 | 2.626,739 | 3,673,436 | |||||||||
| 4. Louis Gleckel, MD | 9,285,671 | 2,667,079 | 3,673,436 | |||||||||
| 5. Mark Leventhal | 9,326,471 | 2,626,279 | 3,673,436 | |||||||||
|
2. |
To ratify the appointment of EisnerAmper LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2017: |
| For | Against | Abstentions | Broker Non-Votes | ||||||||
| 13,157,801 | 98,059 | 2,370,326 | – | ||||||||
About PROPHASE LABS, INC. (NASDAQ:PRPH)
ProPhase Labs, Inc. is a manufacturer, marketer and distributor of a range of homeopathic and health products. The Company is also engaged in the research and development of over-the-counter (OTC) drugs, natural base health products along with supplements, personal care and cosmeceutical products. It is engaged in manufacturing, distributing, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. It also manufactures, markets and distributes an organic cough drop and a Vitamin C supplement, Organix, and performs contract manufacturing services of cough drop, dietary supplements, and other OTC cold remedy products for third parties. Its product pipeline includes Cold-EEZE Cold Remedy QuickMelts and Cold-EEZE Cold Remedy Oral Spray. It also produces Legendz XL for sexual health, Triple Edge XL, which is a daily energy booster plus testosterone support, and Super ProstaFlow Plus for prostate and urinary health. PROPHASE LABS, INC. (NASDAQ:PRPH) Recent Trading Information
PROPHASE LABS, INC. (NASDAQ:PRPH) closed its last trading session down -0.04 at 1.92 with 16,623 shares trading hands.
